The Study
Effect of obicetrapib, a potent cholesteryl ester transfer protein inhibitor, on p-tau217 levels in patients with cardiovascular disease
This study gave people a pill or a sugar pill and saw that the real pill made certain brain markers in their blood change less over a year. It doesn't prove the pill stops Alzheimer's, but it does show it affects the signs we think are linked to Alzheimer's.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
Scientists tested a pill called obicetrapib in people with heart disease who carry a gene (APOE4) that raises Alzheimer’s risk. The pill changed their blood markers linked to brain damage.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 588 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1These changes suggest the pill may delay the brain damage that leads to Alzheimer’s — especially in people with the highest genetic risk who currently have no prevention options.
- 2In people with two copies of APOE4, the pill stopped p-tau217 from rising (it went down 7.81%) while placebo made it rise 12.67%.
- 3It also lowered GFAP by 15.24% and NfL by 17.31% — signs of less brain inflammation and nerve damage.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
The Journal of Prevention of Alzheimer's Disease
Year
2025
Authors
Michael H. Davidson, M. Szarek, P. Scheltens, E. Vijverberg, A. Hsieh, M. Ditmarsch, D. Kling, D. Curcio, Stephen J. Nicholls, Kausik K Ray, Jeffrey L. Cummings, J. Kastelein
Related Content
Claims (6)
In adults with atherosclerotic cardiovascular disease, higher levels of obicetrapib in the blood are associated with lower levels of p-tau217, a biomarker linked to Alzheimer’s disease.
Taking 10 mg of obicetrapib daily for one year reduces the rise in a blood biomarker called phosphorylated tau-217 by 2.84% compared to a placebo in adults with atherosclerotic cardiovascular disease. In individuals with two copies of the ApoE4 gene, the reduction in biomarker increase is 20.48% compared to placebo.
In adults with a specific genetic profile and heart disease, taking obicetrapib for 12 months lowers levels of two blood biomarkers associated with brain cell damage and inflammation compared to a placebo.
In adults with atherosclerotic cardiovascular disease who carry two copies of the ApoE4 gene, taking obicetrapib for 12 months lowers the p-tau217/Aβ42:40 ratio by 22.65% compared to a placebo, reflecting a reduction in tau phosphorylation and amyloid pathology.
In adults with heart disease and two copies of the ApoE4 gene, obicetrapib reduces the number of people whose plasma p-tau217 levels rise above 0.42 pg/mL over 12 months by 46% compared to those taking a placebo.
Obicetrapib lowers a specific blood marker linked to Alzheimer's disease in people with the APOE4 gene variant.
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.